Curve Inks Mammoth Deal With MSD Just Three Years After $6.1m Seed Funding

Could Receive Up To $1.7bn

The young UK biotech will work with MSD to discover up to five targets focused on the neurology and oncology space using its potentially ground-breaking Microcycle drug discovery technology.  

Picture of the University of Southampton building
Early Microcycle Research Was Led At The University Of Southampton • Source: Alamy

Curve Therapeuticscould receive up to $1.7bn after clinching an impressive partnership deal with MSD based on its novel Microcycle technology just a few years after modest seed funding of $6.1m.

Together, the companies will discover and validate up to five therapeutic targets using Microcycle with an initial focus on neurology...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.